Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johannes Winkler

Showing results (1-10 of 86) with videos related to

Pageof 9
Sort By:
Therapeutic Delivery|February 10, 2012
Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotidesJohannes Winkler
Future Medicinal Chemistry|October 15, 2015
Therapeutic oligonucleotides with polyethylene glycol modificationsJohannes Winkler
Therapeutic Delivery|July 26, 2013
Oligonucleotide conjugates for therapeutic applicationsJohannes Winkler
Nucleic Acid Therapeutics|May 8, 2018
Extrahepatic Targeting of Oligonucleotides with Receptor-Binding Non-Immunoglobulin Scaffold ProteinsJohannes Winkler
Expert Opinion on Biological Therapy|March 5, 2013
Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotidesMehrdad Dirin, Johannes Winkler
Methods in Molecular Biology (Clifton, N.J.)|March 7, 2019
Covalent Fluorophore Labeling of Oligonucleotides and Generation of Other Oligonucleotide BioconjugatesCornelia Lorenzer, Johannes Winkler
Future Medicinal Chemistry|December 16, 2014
miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agentsVolker Baumann, Johannes Winkler
Nucleosides, Nucleotides & Nucleic Acids|December 7, 2007
Oligonucleotide charge reversal: 2'-O-lysylaminohexyl modified oligonucleotidesJohannes Winkler, Christian R Noe
Biochimica Et Biophysica Acta|June 14, 2005
Embryonic stem cells for basic research and potential clinical applications in cardiologyJohannes Winkler, Jürgen Hescheler, Agapios Sachinidis
Molecular & Cellular Oncology|June 17, 2016
Novel targets for ATM-deficient malignanciesJohannes Winkler, Kay Hofmann, Shuhua Chen
Pageof 9

Showing results (1-10 of 86) with videos related to

Sort By:
Pageof 9
Therapeutic Delivery|February 10, 2012
Nanomedicines based on recombinant fusion proteins for targeting therapeutic siRNA oligonucleotidesJohannes Winkler
Future Medicinal Chemistry|October 15, 2015
Therapeutic oligonucleotides with polyethylene glycol modificationsJohannes Winkler
Therapeutic Delivery|July 26, 2013
Oligonucleotide conjugates for therapeutic applicationsJohannes Winkler
Nucleic Acid Therapeutics|May 8, 2018
Extrahepatic Targeting of Oligonucleotides with Receptor-Binding Non-Immunoglobulin Scaffold ProteinsJohannes Winkler
Expert Opinion on Biological Therapy|March 5, 2013
Influence of diverse chemical modifications on the ADME characteristics and toxicology of antisense oligonucleotidesMehrdad Dirin, Johannes Winkler
Methods in Molecular Biology (Clifton, N.J.)|March 7, 2019
Covalent Fluorophore Labeling of Oligonucleotides and Generation of Other Oligonucleotide BioconjugatesCornelia Lorenzer, Johannes Winkler
Future Medicinal Chemistry|December 16, 2014
miRNA-based therapies: strategies and delivery platforms for oligonucleotide and non-oligonucleotide agentsVolker Baumann, Johannes Winkler
Nucleosides, Nucleotides & Nucleic Acids|December 7, 2007
Oligonucleotide charge reversal: 2'-O-lysylaminohexyl modified oligonucleotidesJohannes Winkler, Christian R Noe
Biochimica Et Biophysica Acta|June 14, 2005
Embryonic stem cells for basic research and potential clinical applications in cardiologyJohannes Winkler, Jürgen Hescheler, Agapios Sachinidis
Molecular & Cellular Oncology|June 17, 2016
Novel targets for ATM-deficient malignanciesJohannes Winkler, Kay Hofmann, Shuhua Chen
Pageof 9